Navigation Links
Dendreon Reports Fourth Quarter and 2008 Year End Financial Results
Date:3/12/2009

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today reported results for the year and quarter ended December 31, 2008. Revenues for the year ended December 31, 2008 were $111,000 compared to $743,000 for the year ended December 31, 2007. Revenues for the fourth quarter of 2008 were $28,000, compared to $28,000 for the same period in 2007.

The net loss for the year ended December 31, 2008 was $71.6 million, or $0.79 per share, compared to $99.3 million, or $1.20 per share for the year ended December 31, 2007. Net loss in the fourth quarter of 2008 was $8.8 million or $0.09 per share, compared to a net loss of $27.0 million, or $0.32 per share, for the same period in 2007. Dendreon's total operating expenses for the year ended December 31, 2008 were $70.6 million compared to $102.4 million in 2007.

As of December 31, 2008, Dendreon had approximately $108.5 million in cash, cash equivalents, and short-term and long-term investments compared to $120.6 million as of December 31, 2007.

Recent Highlights:

  • Completed the planned interim analysis of the Phase 3, randomized, double-blind, placebo-controlled IMPACT clinical trial designed to assess the safety and efficacy of the investigational active cellular immunotherapy PROVENGE(R) (sipuleucel-T) in men with androgen-independent prostate cancer. While Dendreon remains blinded to the data, the independent data monitoring committee (IDMC) reported to Dendreon a 20 percent reduction in the risk of death in the PROVENGE arm relative to placebo (Hazard Ratio= 0.80; 95% Confidence Interval [0.610-1.051]). The IDMC observed no safety concerns and recommended that the study continue to its final analysis, which is expected to be completed by the end of April 2009
  • Filed an Invest
    '/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
8. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
9. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
10. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
11. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... OHAUS Corporation, a leading worldwide ... and scales, proudly announces its Explorer line of ... magazine’s 2014 “Readers' Choice” Award for best ... Explorer was voted the best laboratory balance by ... celebrates “excellence in product design and performance for ...
(Date:7/22/2014)... SHENZHEN , Kina, 22. juli 2014 ... Tech), et datterselskab af BGI, verdens største genomics-organisation, ... whole exome-sekvenseringstjeneste baseret på Complete Genomics brancheførende platform. ... branchen for at levere patenterede sekvenseringsteknologier med 99,999 ... varianter, blev købt af BGI i 2013. Mere ...
(Date:7/22/2014)... CAMBRIDGE, Massachusetts en SHENZHEN, China ... Solutions Co., LTD, (BGI Tech), een dochtermaatschappij van BGI, ... kondigde de wereldwijde introductie aan van een nieuwe service ... de sector meest geavanceerde platform van Complete Genomics. ... bedrijf dat binnen de sector in hoog aanzien staat ...
(Date:7/22/2014)... 22, 2014 Hussey Copper , a ... antimicrobial copper announces Pullman Regional Hospital,s conversion of ... antimicrobial solid touch surface, at a nominal cost.  This ... E-coli and other bacteria within 2 hours of exposure 1 ... bacteria and infectious diseases in its facilities. ...
Breaking Biology Technology:OHAUS Explorer Voted “Best Balance” in Laboratory Equipment’s 2014 Readers’ Choice Awards 2BGI Tech lancerer Human Whole Exome-sekvenseringstjeneste på Complete Genomics avancerede platform 2BGI Tech introduceert service op gebied van hele menselijke exoomsequencing op geavanceerd Complete Genomics-platform 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Pullman Regional Hospital changes more than 1,100 touch points to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3
... , CALGARY, Nov. 17 /PRNewswire-FirstCall/ - ... or the "Company") today announced updated results from ... REOLYSIN(R) combined with paclitaxel/carboplatin for patients with advanced ... AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference being ...
... ... demand creation, social media, sales readiness and channel effectiveness to be revealed at SiriusDecisions ... ... for business-to-business sales and marketing best practice research and data, today announced that transformation ...
... ... for Sabalcore customers. , ... (PRWEB) November 17, 2009 -- Sabalcore Computing Inc. has selected ... to Sabalcore customers. "We chose Scalable Informatics because of their depth of experience, ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting 3Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010 2Learn Proven Practices to Measure, Align and Transform at SiriusDecisions Sales and Marketing Summit 2010 3Sabalcore Computing Has Selected Scalable Informatics as Their Primary Storage Vendor 2
(Date:7/22/2014)... the National Institute of Standards and Technology (NIST), ... dramatically improved technique for analyzing biological cells and ... new NIST technique is an advanced form of ... that delivers signals that are 10,000 times stronger ... times stronger than obtained from comparable "coherent Raman" ...
(Date:7/22/2014)... Stem cells offer much promise for treating damaged organs ... survival is poor, limiting their effectiveness. New methods are ... optimize their therapeutic function after transplantation, as described in ... a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ... Open Access website . , In ...
(Date:7/22/2014)... Cambridge, MA and Shenzhen, China July 22, ... Tech), a subsidiary of BGI, the world,s largest ... a new human whole exome sequencing service based ... service includes in-depth bioinformatics analysis and SNP validation, ... 31, 2014. , Complete Genomics, highly regarded ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3BGI Tech launches human whole exome sequencing service on complete genomics' advanced platform 2
... Oregon biologists say they have opened the window on the natural ... they gained could be used to advance therapies for bone fractures ... print in the Feb. 13 issue of the journal Cell ... in concert to allow adult zebra fish to perfectly replace bones ...
... release is available in German . ... of thousands of neurons in the brain. Nerve growth factors produced ... neurons; however, clinical tests with GDNF have not yielded in any ... Martinsried and their colleagues have now succeeded in demonstrating that GDNF ...
... of colour is more similar to a dog than a ... evolved so selectively. By developing a pokies-like game for ... ONE by Curtin University,s Dr Wiebke Ebeling and colleagues ... and how their colour perception differed from other species. ...
Cached Biology News:Zebra fish fins help Oregon researchers gain insight into bone regeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 2Parkinson gene: Nerve growth factor halts mitochondrial degeneration 3Research shows wallabies lose on the pokies 2
Request Info...
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
...
Biology Products: